Blood glucose control is the primary strategy to prevent complications in diabetes. At the onset of kidney disease, therapies that inhibit components of the renin angiotensin system (RAS) are also indicated, but these approaches are not wholly effective. Here, we show that once daily administration of the novel glucose lowering agent, empagliflozin, an SGLT2 inhibitor which targets the kidney to block glucose reabsorption, has the potential to improve kidney disease in type 2 diabetes. In male db/db mice, a 10-week treatment with empagliflozin attenuated the diabetes-induced upregulation of profibrotic gene markers, fibronectin and transforming-growth-factor-beta. Other molecular (collagen IV and connective tissue growth factor) and histological (tubulointerstitial total collagen and glomerular collagen IV accumulation) benefits were seen upon dual therapy with metformin. Albuminuria, urinary markers of tubule damage (kidney injury molecule-1, KIM-1 and neutrophil gelatinaseassociated lipocalin, NGAL), kidney growth, and glomerulosclerosis, however, were not improved with empagliflozin or metformin, and plasma and intra-renal renin activity was enhanced with empagliflozin. In this model, blood glucose lowering with empagliflozin attenuated some molecular and histological markers of fibrosis but, as per treatment with metformin, did not provide complete renoprotection. Further research to refine the treatment regimen in type 2 diabetes and nephropathy is warranted.
Diabetic nephropathy accounts for 35-40% of new cases of end-stage renal disease in the developed world 1,2 . A major risk factor for the vascular complications of diabetes is chronic elevations in blood glucose concentrations (hyperglycemia) but there is no guarantee that glycemic control will prevent the onset and progression of micro-and/or macrovascular diseases [3] [4] [5] [6] . At the first clinical sign of renal impairment (albuminuria), inhibitors of the renin-angiotensin system (RAS) are administered but they only slow progression of the disease 4 . Therefore, anti-diabetic strategies that effectively control blood glucose levels and prevent the onset and progression of diabetic nephropathy are in great demand.
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Sodium-dependent glucose transporter (SGLT)-2 inhibitors, a new anti-diabetic strategy, target the renal proximal tubules to block glucose reabsorption, thereby enhancing urinary glucose excretion and conferring anti-hyperglycemic effects. They are indicated for use in individuals with type 2 diabetes (provided kidney function is at least moderate) and are under clinical investigation as an add-on to exogenous insulin in type 1 diabetes. Clinical studies with SGLT2 inhibitors have reported reductions in fasting plasma glucose and glycated hemoglobin (HbA 1c ) levels (0.7-0.8%) compared to placebo and other glucose lowering strategies [7] [8] [9] [10] [11] , and a reduction in cardiovascular mortality in individuals with type 2 diabetes and high cardiovascular risk 12 .
Under normal conditions, glucose is almost completely reabsorbed from the urinary filtrate by secondary active co-transporters located on the apical membrane, SGLT2 and SGLT1, in the early and late proximal tubule, respectively 13 . SGLT2 is responsible for the majority (up to 97%) of glucose reabsorption, while SGLT1 reabsorbs the majority of remaining luminal glucose. At the basolateral side, GLUT2 is responsible for the majority of glucose transport from the cells into the interstitium and peritubular circulation. In diabetes, the maximal threshold for glucose reabsorption is increased 14, 15 . This contributes to hyperglycemia and, potentially, diabetic nephropathy via proximal tubular glucotoxicity.
While there is much focus on the role of glomeruli, tubulointerstitial changes more closely correlate with the clinical progression of nephropathy in diabetes [16] [17] [18] . Previous studies using human proximal tubular cells (HK2) reported that SGLT2 inhibition decreased the production of inflammatory and fibrotic markers induced by high glucose 19 . These in vitro findings suggest that SGLT2 inhibitors may provide renoprotection in diabetes by averting glucose from entering proximal tubule cells 20, 21 . However, in recent preclinical studies, renoprotection with SGLT2 inhibition has been seen only when blood glucose levels were markedly improved [20] [21] [22] [23] [24] [25] . Thus, the effect of SGLT2 inhibition on early kidney growth, inflammation, and fibrosis was proposed to result from blood glucose lowering 21 . The effect of SGLT2 inhibition on diabetic nephropathy, independent of blood glucose lowering, was assessed in diabetic eNOS knockout mice 26 . Blood glucose levels were matched between diabetic groups using insulin (group means > 20 mmol/L) and, unlike an angiotensin receptor blocker, empagliflozin did not provide renoprotection. These data highlight that, in models of early diabetic nephropathy, renoprotection from hyperglycemia may be afforded only when circulating glucose levels and/or the activity of the RAS are sufficiently decreased.
In this study, we aimed to determine whether the administration of an SGLT2 inhibitor, empagliflozin, improves early manifestations of diabetic nephropathy in the db/db mouse model of type 2 diabetes. This model harbors a spontaneous mutation of the leptin receptor and is characterized by polyphagia, obesity, insulin resistance, hyperglycemia, pancreatic β -cell failure, and kidney and cardiovascular complications that are akin to type 2 diabetes in humans. We further aimed to determine whether the renoprotection offered by empagliflozin was associated with lowering of blood glucose concentrations, intrarenal RAS activity, and/or glucose content within kidney cortices. Whether these renal benefits were superior to the first-line, glucose-lowering therapy for type 2 diabetes, metformin, and/or additive upon empagliflozin and metformin dual therapy, were also assessed.
Results
Body weight and metabolic parameters. In this study, db/db and db/m littermates were treated with empagliflozin (10 mg/kg/day) or vehicle by single daily oral gavage for 10 weeks. Two additional db/db groups were included and treated with the first-line anti-diabetic agent, metformin (250 mg/kg/day), or empagliflozin and metformin co-therapy (as per mono-therapy dosages). At treatment commencement (baseline; 10 weeks of age), db/db mice were ~14 g heavier (>1.5-fold, Table 1 ) with higher fasting blood and plasma glucose concentrations compared to non-diabetic db/m mice (Fig. 1a,c) . Between weeks five and 10 of treatment, db/db mice administered with vehicle or metformin lost 3.0 and 4.4 g, respectively, whilst empagliflozin monotherapy maintained body weight and co-treated mice gained 3.1 g (Table 1 ). This may relate to differences in circulating insulin Fig. 2 ). For db/m mice, both vehicle-(P = 0.07) and empagliflozin-treated groups gained 1.0 g between weeks five and 10 of treatment (Table 1) . At 10 weeks of treatment (20 weeks of age), db/db mice treated with empagliflozin were 8 to 11 g heavier than vehicle-and metformin-only-treated mice (Table 1) .
Blood and plasma glucose concentrations were measured 20-24 h after the previous day's therapy. Three days after the commencement of treatment, all mice treated with empagliflozin had lower fasting blood glucose levels compared to db/db vehicle and all intervention arms had considerable reductions from baseline (Fig. 1a,b) . By the study end, SGLT2 inhibitor monotherapy lowered fasting plasma glucose levels to 18 mmol/L compared to 27 mmol/L in db/db vehicle (Fig. 1c) . In addition, glycated hemoglobin was restored to non-diabetic levels, achieving 6.6% compared to 9.6% in db/db vehicle (Fig. 1e) . Co-therapy with metformin provided modest incremental benefits, lowering fasting plasma glucose to 16 mmol/L, which was also reduced from baseline, and glycated hemoglobin to 5.7% (Fig. 1c-e) . Metformin monotherapy tended to reduce fasting plasma glucose (20 mmol/L) and glycated hemoglobin (8.0%) compared to db/db vehicle (P = 0.079 and P = 0.062, respectively, Fig. 1c,e) .
All db/db mice consumed more food and water, and produced more urine compared to db/m when assessed at two and six weeks into the treatment period (Table 1 ). There were no effects of treatment on food intake but, in the db/m mice, empagliflozin increased water consumption at six weeks (P = 0.066) and urine output at both ages (two weeks P = 0.055, Table 1 ). reduced plasma glucose levels at baseline and at 60 and 120 mins after the glucose bolus compared to vehicle db/db mice, resulting in a reduced AUC glucose (Fig. 2a,b) . Co-therapy decreased plasma glucose concentrations at baseline, and at 15, 60, and 120 mins of the OGTT, and reduced AUC glucose compared to vehicle-and metformin-treated db/db mice (Fig. 2a,b) . Metformin monotherapy did not improved glucose tolerance during the OGTT (Fig. 2a,b) .
Plasma insulin concentrations were increased throughout the OGTT in co-treated mice and at specific time points (0, 15, 30, and 60 mins) in empagliflozin mono-treated mice compared to db/m (Fig. 2c) . Co-therapy also resulted in elevated plasma insulin levels throughout the OGTT when compared to diabetic vehicle-and metformin-treated mice, whilst empagliflozin increased insulin at baseline and 15 mins only (Fig. 2c) . Vehicle-, empagliflozin-, and co-treated diabetic mice had elevated area under the insulin curve (AUC insulin ) compared to non-diabetic and this difference was most pronounced for the latter, which also had enhanced insulin response when compared to all other db/db groups (Fig. 2d) . Vehicle-and metformin-treated db/db mice exhibited a 50-60% reduction in the insulinogenic index (AUC insulin:glucose 0-30 mins ), and empagliflozin, as a single and dual therapy with metformin, restored and further increased this index compared to db/m levels, respectively (Fig. 2e) . Fasting plasma glucose-to-insulin ratio was reduced in the co-treated mice when compared to vehicle-and metformin-treated diabetic mice as well as non-diabetic db/m mice (Fig. 2f) , indicative of reduced insulin sensitivity. Empagliflozin mono-therapy also tended to reduce this ratio when compared to the metformin-treated diabetic arm (P = 0.089, Fig. 2f ). HOMA-IR was elevated in all diabetic mice and exacerbated in the co-treated group (see Supplementary Fig. S1a ). Insulin positivity within pancreatic islets was not different between non-diabetic and diabetic vehicle-treated mice (see Supplementary Fig. S1b ). Co-therapy, however, increased insulin positive staining in db/db mice compared to db/m vehicle and other diabetic groups, whilst metformin reduced insulin positivity compared to vehicle-treated counterparts (see Supplementary Fig. S1b ). Empagliflozin increased islet insulin content when administered to db/m mice (see Supplementary Fig. S1b ).
Renal glucose handling, and expression of glucose transporters and gluconeogenic enzymes. The predicted filtered glucose load, assessed after eight weeks of treatment, was increased in all db/ db mice (Fig. 3a,b) . Empagliflozin (mono-and co-therapy) reduced the filtered glucose load by 45% compared to db/db vehicle, owing to a similar reduction in fasted plasma glucose levels ( Fig. 3a) . In db/db mice treated with empagliflozin monotherapy, reduced filtered glucose load was also mediated by a modest reduction in glomerular filtration rate (GFR; P = 0.059, Fig. 3b ). All db/db mice had glucosuria, excreting ~1500 mg glucose into their urine each day, compared with < 0.2 mg in db/m vehicle (Fig. 3c) . Empagliflozin in non-diabetic mice increased urinary glucose excretion to > 80 mg per day (Fig. 3c ) without affecting circulating glucose concentrations compared to vehicle counterparts (see above; Fig. 1 ). In mice with diabetes, empagliflozin monotherapy caused a left-ward shift in the relationship between plasma glucose level and urinary glucose, indicating that urinary glucose excretion was greater for any given concentration of plasma glucose (see Supplementary Fig. S2a ). This treatment effect was lost when empagliflozin was co-administered with metformin and absent in metformin-treated mice (see Supplementary Fig. S2b,c ). These observations with respect to glucosuria, measured after six weeks of treatment, were also evident after two weeks of treatment (data not shown). Cytosolic glucose concentrations within renal cortices, determined in tissue that was harvested from fasted mice ~24 h after the last dose, were increased in all db/db mice compared to db/m, and exacerbated by metformin mono-therapy (Fig. 3d) . Empagliflozin, either as a mono-therapy or co-therapy with metformin, did not reduce cortical glucose content (Fig. 3d) .
Compared with db/m mice, the expression of genes encoding SGLT1 (Slc5a1), SGLT2 (Slc5a2), and GLUT2 (Slc2a2) were elevated in all diabetic mice, except for those administered co-therapy (Fig. 4a-c) . Co-treatment substantially reduced the diabetes-induced upregulation of Slc2a2, but not Slc5a1 and Slc5a2, mRNA levels when compared to all other diabetic arms (Fig. 4a-c) . In non-diabetic db/m mice, empagliflozin tended to increase gene expression of Slc5a1 (P = 0.091), but did not affect Slc5a2 and Slc2a2 expression (Fig. 4a-c) . Renal cortical protein concentration of SGLT2, in total cell membranes, was not different between groups (Fig. 4d,e) .
Renal cortical expression of Pck1, encoding a key gluconeogenic enzyme, PEPCK, was increased in all db/db groups (Fig. 5a) . Fbp1, which encodes the rate-limiting fructose-1,6-bisphosphatase 1 enzyme, was also increased in metformin and tended to be increased in co-treated (P = 0.097) diabetic mice (Fig. 5b) . G6pc, encoding for the enzyme, glucose-6-phophatase, tended to be increased in co-treated mice only (P = 0.067, Fig. 5c ). Metformin-treated db/db mice tended to have greater expression of Pck1 and Fbp1 when compared to diabetic mice treated with empagliflozin (P = 0.051 and P = 0.062, Fig. 5a,b) .
Renal function. All db/db mice had albuminuria at two, six and 10 weeks of treatment which remained unaffected by any treatment regimen (Fig. 6a-c) . Empagliflozin in the non-diabetic db/m mice increased urinary albumin excretion by > 2-fold at 6 weeks of treatment (Fig. 6b) , due to a similar increase in urine production (see above; Table 1 ). Urinary excretion of renal tubule damage markers, KIM-1 and NGAL, were ~40 times higher in db/db vs db/m, without an effect of treatment (Fig. 6d,e) . Urinary NGAL in non-diabetic mice treated with empagliflozin was also increased; attributed to increased urine production (see above; Table 1 ). In all db/db mice, except those treated with the combination therapy, plasma cystatin C was reduced by ~22%, indicative of glomerular hyperfiltration (Fig. 6f) . In db/m mice, empagliflozin tended to increase plasma cystatin C levels (+ 17%, P = 0.064, Fig. 6f ), suggesting a small decrease in GFR.
Renal morphology and expression of profibrotic genes. Compared to db/m, kidney weight was ~23% greater in db/db vehicle-, empagliflozin-, and co-treated mice but 43% greater in metformin-treated mice (Table 1) . Glomerulosclerosis (PAS-positive staining) was elevated in all db/ db mice and unaffected by treatment (Fig. 7a,b) . Glomerular collagen IV and fibronectin accumulation tended to be higher in vehicle-treated diabetic vs non-diabetic mice (P = 0.054 and P = 0.095, respectively, Fig. 7c-f ). This diabetes-induced deposition of glomerular collagen IV and fibronectin was absent in all treated arms, except for the latter which remained elevated in metformin-treated mice (Fig. 7c-f) . Total collagen accumulation within renal cortical/outer medullary regions was increased in all db/db mice compared to db/m when quantified using Masson's trichrome (P < 0.05), but not Sirius Red, staining ( Fig. 8a-d) . Co-treatment with empagliflozin and metformin tended to reduce Masson's trichrome positivity (P = 0.088) and significantly decreased Sirius Red staining when compared to db/db vehicle ( Fig. 8a-d) . The degree of tubulointerstitial collagen IV and fibronectin staining, however, was not different among groups (Fig. 8e-h) .
Renal cortical expression of ColIVα1, Fn1, Ctgf, Tgfβ1, and the cell surface macrophage marker, Cd14, were elevated in vehicle-treated diabetic vs non-diabetic mice (Fig. 9a-e) . In mice treated with empagliflozin, the diabetes-induced upregulation of Tgfβ1 and Cd14 was absent and there was a trend for reduced Fn1 expression compared to vehicle-treated db/db mice (P = 0.059, Fig. 9b,d,e) . ColIVα and Ctgf, however, remained elevated in empagliflozin-treated diabetic vs non-diabetic mice (Fig. 9a,c) . Metformin did not restore the diabetes-induced upregulation of any genes but tended to decrease Fn1 (P = 0.095) and Tgfβ1 (P = 0.068) compared to db/db vehicle (Fig. 9a-e) . Co-administration of empagliflozin and metformin provided the greatest benefits, such that the diabetes-induced upregulation of all genes was no longer present in this group, except for Ctgf expression which remained elevated compared to non-diabetic levels (Fig. 9a-e) . Ctgf expression was, however, reduced when compared to other db/db groups (P = 0.096 vs vehicle, P < 0.05 vs empagliflozin, P = 0.070 vs metformin, Fig. 9c ). Of note, in non-diabetic mice, empagliflozin increased the renal cortical expression of ColIVα1 but did not affect the expression of any other genes (Fig. 9a-e) .
Plasma renin activity, and intra-renal renin activity and angiotensin II content. Plasma renin activity tended to increase in diabetic vs non-diabetic vehicle-treated counterparts (P = 0.058, Fig. 10a ). Empagliflozin treatment increased plasma renin activity in non-diabetic mice, and both empagliflozin (P = 0.059) and metformin mono-therapies exacerbated this diabetes-induced increase (Fig. 10a) . Renin activity in renal cortices was not different between non-diabetic and diabetic mice administered with vehicle (Fig. 10b) . However, empagliflozin increased intra-renal renin activity levels in both non-diabetic and diabetic mice (Fig. 10b) . Combination therapy exacerbated this increase in cortical renin activity but metformin mono-therapy had no effect compared to vehicle-treated diabetic mice (Fig. 10b) . Renal cortical levels of angiotensin II were not different between db/m and db/db vehicle-treated mice, however, an increasing trend was seen in the metformin-treated group vs db/m vehicle (P = 0.096) and db/db empagliflozin (P = 0.055, Fig. 10c ).
Discussion
In the present study, we demonstrate in the db/db mouse model of type 2 diabetes that upregulation of some profibrotic genes in the kidney was ameliorated upon SGLT2 inhibition, parallel to the effects of metformin. When empagliflozin and metformin were co-administered, additional molecular and histological markers of kidney fibrosis were attenuated. Diabetes-induced upregulation of renal Cd14 was also no longer present in the mice treated with empagliflozin (mono-and co-treatment with metformin), but not metformin, suggesting that the aforementioned benefits with SGLT2 inhibition may have been mediated through reduced inflammation. However, empagliflozin did not improve diabetes-induced albuminuria, increased urinary markers of tubule damage (KIM-1 and NGAL), renal hypertrophy, or glomerulosclerosis, when administered alone or in combination with metformin. These partial benefits occurred in line with a modest lowering of blood glucose that remained above non-diabetic levels. Thus, in light of our findings and others 26 , who have failed to observe complete restoration of kidney function, the determinants of renoprotection with SGLT2 inhibition in diabetes warrant further consideration.
Previously, in db/db mice, the administration of an SGLT2 inhibitor; dapagliflozin in males 23 and tofogliflozin in females 25 , prevented progressive albuminuria, parallel to the effect of losartan in the latter study, and lowered plasma glucose levels to < 15 mmol/L. In male db/db mice treated with empagliflozin, Lin et al. similarly demonstrated reduced albuminuria and glomerulosclerosis, associated with complete amelioration of hyperglycemia 24 . Vallon et al., also demonstrated that empagliflozin administered to male Akita/+ mice, a model of type 1 diabetes, reduced albuminuria, renal hypertrophy, and markers of inflammation, which was in proportion to blood glucose lowering (average ~11 mmol/L) 21 . The timing and degree of blood glucose lowering, and dose of therapy are the major differences between the current study and previous reports of significant renoprotection. We commenced treatment two to three weeks later than that of Terami et al. 23 , Lin et al. 24 , and Nagata et al. 25 , and plasma glucose remained > 15 mmol/L in our study. The dose of empagliflozin administered to Akita/+ mice in Vallon et al. and db/db mice in Lin et al. equates to four to six times that of the current study, which was provided ad libitum in food, and likely contributes to the pronounced blood glucose lowering and renoprotection seen in those studies 21, 24 . Despite restoration of glycated hemoglobin levels with empagliflozin in our study, it is likely that plasma glucose levels fluctuated around the single daily administration, reaching spikes of 18 and 16 mmol/L in mono-and co-treated groups, respectively, compared to 6.5 mmol/L in non-diabetic vehicle-treated mice. We determined the circulating glucose level 20-24 h after the previous day's gavage; likely at a peak glucose concentration given that empagliflozin half-life is ~5.6 h in the male mouse. Indeed, the benefits of early and intensive blood glucose lowering for microvascular complications are well established 27, 28 and fluctuations in glucose level are known to increase the risk of complications independent of average glucose exposure 29 . It is therefore likely that renal structures remained exposed to hyperglycemia, at least temporally, in this study. We did not assess blood glucose variation by continuous monitoring in the present study. In type 2 diabetic patients, twice daily treatment with empagliflozin as an add-on to metformin was not superior to once daily treatment in terms of blood glucose lowering 30 . However, long-term microvascular outcomes from this treatment regimen are yet to be determined. Future pre-clinical and clinical studies on renal outcomes would benefit from early and multiple daily dosing of empagliflozin, continuous glucose monitoring, and the risk to benefit ratio of higher doses closely monitored.
We observed that SGLT2 inhibition in db/db mice reduced the filtered glucose load which, based on previous in vitro findings, was expected to downregulate markers of proximal tubular damage 19, [31] [32] [33] , and translate into functional improvements for the kidney. However, clinical features of diabetic nephropathy, including albuminuria, urinary markers of tubule damage (KIM-1 and NGAL), kidney growth, and glomerulosclerosis were not improved in this study, even when empagliflozin was co-administered with metformin. Empagliflozin is expected to reduce the tubular max (T max ) for glucose reabsorption which, together with reduced filtered load, would theoretically reduce glucose content within proximal tubule cells. However, in non-diabetic and diabetic mice, empagliflozin did not reduce cortical glucose content when compared to vehicle. Whilst the establishment of an inward glucose gradient at the basolateral surface may occur with SGLT2 inhibition 13 , the reduction in plasma glucose levels with empagliflozin as well as reduced cortical expression of Slc2a2 (encoding GLUT2) with co-therapy, argues against this possibility. Although unlikely to fully account for unchanged cortical glucose content, an explanation may be enhanced SGLT1-mediated glucose reabsorption, as seen previously under SGLT2 blockade 34 . In this study, kidney mRNA levels of three key gluconeogenic enzymes, Pck1, Fbp1, and G6pc, were not enhanced by empagliflozin suggesting there was no compensatory increase in renal gluconeogenesis. This is in agreement with another study where kidney Pck1 levels were reduced in Akita/+ mice treated with empagliflozin 21 . Endogenous glucose production (EGP) is enhanced by SGLT2 inhibition in humans 35, 36 and, given the abovementioned findings in mice, this may primarily be of hepatic origin. We observed that the diabetes-induced increase in renal gluconeogenic gene expression (Pck1 and Fbp1) was exacerbated by metformin. This may be explained by compensatory EGP from renal sources, if metformin specifically suppresses hepatic gluconeogenesis 37, 38 , although this remains to be tested in future studies. SGLT2 inhibition increased both plasma and intrarenal renin activity in diabetic and non-diabetic mice. In line with this, eight-week treatment with empagliflozin in individuals with type 1 diabetes increased circulating angiotensin II levels 9 , albeit, in our study, intrarenal angiotensin II content remained unchanged. Increased RAS activity with SGLT2 inhibition is explained by the expected volume depletion with this class of therapy 39 . Despite a tendency for reduced GFR with SGLT2 inhibition, likely due to increased afferent tone via tubuloglomerular feedback 40 , we cannot rule out relevant increases in efferent tone via activation of the RAS; which could increase intraglomerular pressure. RAS inhibition may also restore glomerular function independent of increased capillary pressure 41 and thus the benefits afforded by dual RAS-SGLT2 inhibition warrant further study. Indeed, in Dahl salt-sensitive diabetic rats, maximal renoprotection from glomerular injury, renal fibrosis, and proteinuria was achieved when luseogliflozin was combined with the ACE inhibitor, lisinopril 42 . In our studies, SGLT2 inhibition increased fasting and glucose-stimulated plasma insulin levels, which was most profound in mice that received dual therapy with metformin, and may account for their weight gain over time. This is contrary to the weight loss reported in obese individuals treated with an SGLT2 inhibitor 7 , however, Lin et al. demonstrated similar increases in plasma insulin and body weight in db/db mice, along with improvements in albuminuria and glomerulosclerosis 24 . Thus, increased body weight cannot account for the only modest renoprotective effects of SGLT2 inhibition seen in our study. Of note, as per empagliflozin, the anti-hyperglycemic agent metformin was unable to prevent albuminuria but attenuated kidney Fn1 and Tgfβ expression. Interestingly, treatment with metformin exacerbated diabetic kidney growth which warrants additional study. We demonstrated efficacy in our studies by the presence of glucosuria in non-diabetic mice that were treated with empagliflozin. As seen previously in STZ-diabetic, Akita/+ and db/db mice 20, 21, 24, 25 , SGLT2 inhibition did not exacerbate diabetes-induced glucosuria, which is explained by the reduction in filtered glucose load equalling the degree of SGLT2 inhibition. Also, given that GFR remained sufficient, empagliflozin was able to reach the brush border membrane of the proximal tubule and exert its intended effects 43 . The difference in blood glucose lowering between empagliflozin mono-and co-treated groups was modest, suggesting that other factors beyond glucose lowering may contribute to the superior renal outcomes seen with dual therapy in this study. We observed that fasting and glucose-stimulated insulin secretion was considerably increased in the co-treated mice, along with increased pancreatic insulin content. Further, the leftward shift in the relationship between plasma glucose levels and urinary glucose excretion with empagliflozin was absent in the co-treated mice. The mechanism(s) underlying these findings and their relationship, if any, to kidney fibrosis requires additional study.
SGLT2 inhibitors are a new class of anti-diabetic agent and human studies in type 1 and 2 diabetes have demonstrated efficacy in blood glucose lowering and acute hemodynamic changes in kidney function 9, 44 . Long-term clinical studies on the incidence of microvascular complications, such as diabetic nephropathy, are ongoing and will determine whether SGLT2 inhibitors exert benefits that are superior to traditional agents 13 . While we were unable to show considerable improvements in renal function, the expression of some profibrotic genes was reduced with empagliflozin, in line with the effects of first line anti-diabetic agent, metformin. Additional molecular and histological benefits where offered when empagliflozin and metformin were co-administered. Persistent hyperglycemia and albuminuria-onset prior to commencement of treatment in this model rendered our study an interventional rather than a preventative approach. We suggest that a threshold of blood glucose lowering may be required to achieve renoprotection in diabetes, which may differ for individual parameters, as evidenced by some, but not all, features of kidney disease improving with SGLT2 inhibition in our study. Thus, taken together with previous work, we suggest that early, sufficient, and stable blood glucose lowering, possibly with multiple agents, including higher-and/or multiple daily-dosing of SGLT2 inhibition in combination with RAS blockade, may be required to achieve maximal renoprotection in diabetes. Bar Harbor, ME, USA). Mice were housed in an environmentally controlled room (constant temperature 22 °C), with a 12:12 h light-dark cycle and access to standard chow and tap water ad libitum. At 10 weeks of age, db/db and db/m mice were randomized to receive empagliflozin (10 mg/kg/day; provided by Boehringer-Ingelheim, Germany) or vehicle (0.5% hydroxyethylcellulose, Sigma-Aldrich, St. Louis, MO, USA) by oral gavage for 10 weeks, between the hours of 14:00 and 16:00. Additional db/db mice were administered the anti-hyper glycemic agent, metformin (250 mg/kg/day; Sigma-Aldrich), or empagliflozin + metformin co-therapy (as per mono-therapy dosages). Body weight and fasting blood glucose were monitored throughout the study. Approximately 24 h after the last treatment (20 weeks of age), mice were fasted for ~4 h and anesthetized with sodium pentobarbital (150 mg/kg ip; Virbac, Milperra, NSW, Australia). Kidneys and pancreata were excised, snap-frozen in liquid nitrogen, or fixed in 10% neutral buffered formalin.
Methods

Animals
Food and water intake, and blood and urine collection. At two and six weeks of the treatment period, mice were weighed and placed individually into metabolic cages for 24 h measurements of food and water intake, and urine collection 45, 46 . Blood samples were collected via tail tipping immediately upon removal from metabolic cages. Mice were acclimatized to the metabolic cages by placing them in for short daylight periods on two separate occasions prior to the 24 h collection. Glomerular filtration rate. At week eight, GFR was estimated in conscious mice using the transcutaneous decay of retro-orbitally injected FITC-sinistrin (10 mg/100 g body weight dissolved in 0.9% NaCl), as previously described 47 . Background signal was recorded for one minute, mice were injected under brief inhaled isoflurane anesthesia, and the signal was recorded for 60 min. GFR was calculated using the half-life derived from the rate constant (α 2 ) of the single exponential, excretion phase of the curve and a semi-empirical factor. Plasma cystatin C was also measured at the study end, after 10 weeks of treatment (ELISA, BioVendor, Brno, Czech Republic).
Oral glucose tolerance test. At week eight, an oral glucose tolerance test (OGTT) was performed following a 6 h fast between 08:00-14:00 h 48 . Blood samples were taken via tail tipping prior to (0 min) and following an oral glucose bolus (2 g/kg body wt of 50% w/v D-glucose solution) at 5, 15, 30, 60, and 120 min for determination of plasma glucose and insulin concentrations. The efficacy of insulin secretion was calculated (insulinogenic index; Insulin 30 -Insulin 0 /Glucose 30 -Glucose 0 ) 49 . The ratio of fasting plasma glucose-to-insulin ratio and 
